28 Million Obese Patients Are Expected To Be On GLP-1 Drugs By 2029

In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]

Read full article at https://wccftech.com/28-million-obese-patients-are-expected-to-be-on-glp-1-drugs-by-2029/